Current Funding Opportunities – November 2018

1. **Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS, Second Wave) (UG3/UH3 Clinical Trial Required)) ([RFA-CA-19-018](RFA-CA-19-018))**

Sponsor: NIH NCI

Synopsis: This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative intended to accelerate cancer research. The purpose of this FOA is to promote research in colorectal cancer (CRC) screening, follow-up, and referral-to-care in regions of the United States (U.S.) where screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based approaches.

This FOA will support the expansion of Accelerating Colorectal Cancer Screening and Follow-up through Implementation Science program with a greater emphasis on geographic regions with low colorectal cancer screening. As with the previous issuance, the goal for the expansion is to develop an evidence base for multilevel interventions that increase rates of CRC screening, follow-up, and referral-to-care, and best practices for how multilevel interventions can be scaled-up to reduce the burden of colorectal cancer on the U.S. population.

This expansion of the ACCSIS Program will support UG3/UH3 phased award research projects (under this FOA). A U24 Coordinating Center has been previously funded (through RFA-CA-17-039) and will support both the first and second waves of ACCSIS Research Projects in the ways described in this announcement.

Applicants responding to this FOA must apply for both the UG3 and UH3 phases together in a single application. The Year 1 UG3 Planning-Exploratory Phase is a developmental year for pilot testing and refining a proposed multilevel intervention to increase rates of CRC screening, follow-up and referral-to-care. At the end of Year 1, pilot data should indicate the multilevel intervention is ready for testing in a new, larger, clinical trial. This evidence of readiness will be demonstrated through achievement of scientific milestones and feasibility requirements as proposed in the application. Achievement of these milestones will be necessary for transition to the UH3 Implementation Phase. UH3s will be awarded after administrative review of the UG3 milestones pending availability of funds. During the UH3 phase, Years 2-5, the revised multilevel intervention will be tested in a new, larger clinical trial, using an experimental or quasi-experimental study design. Successful awardees from this FOA will be expected to interact and collaborate with the NCI, other ACCSIS Research Project awardees, and the ACCSIS Coordinating Center.

Application Receipt Date: February 11, 2019, by 5:00 PM local time of applicant organization.

2. **Immuno-Oncology Translation Network (IOTN): Cancer Immunotherapy Research Projects (U01 Clinical Trial Not Allowed) (RFA-CA-19-015)**

Sponsor: NIH NCI

Synopsis: This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers.

The purpose of this FOA is to expand organ site-specific Cancer Immunotherapy Research Projects as components of the Immuno-Oncology Translation Network (IOTN). The IOTN will form an integrated network of multi-disciplinary, collaborative teams with the overarching goals of accelerating translational research of innate and adaptive immune mechanisms that contribute to tumor progression, and evaluating new or improved immunotherapeutic strategies (including combinations with standard or other therapies) that result in durable anti-cancer responses. Studies should be largely pre-clinical involving clinically-relevant models and endpoints.

Application Receipt Dates: February 8, 2019, by 5:00 PM local time of applicant organization.